Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis
- PMID: 23417738
- PMCID: PMC3622327
- DOI: 10.1194/jlr.M034876
Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis
Abstract
We sought to determine whether hepatic cholesterol crystals are present in patients or mice with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH), and whether their presence or distribution correlates with the presence of NASH as compared with simple steatosis. We identified, by filipin staining, free cholesterol within hepatocyte lipid droplets in patients with NASH and in C57BL/6J mice that developed NASH following a high-fat high-cholesterol diet. Under polarized light these lipid droplets exhibited strong birefringence suggesting that some of the cholesterol was present in the form of crystals. Activated Kupffer cells aggregated around dead hepatocytes that included strongly birefringent cholesterol crystals, forming "crown-like structures" similar to those recently described in inflamed visceral adipose tissue. These Kupffer cells appeared to process the lipid of dead hepatocytes turning it into activated lipid-laden "foam cells" with numerous small cholesterol-containing droplets. In contrast, hepatocyte lipid droplets in patients and mice with simple steatosis did not exhibit cholesterol crystals and their Kupffer cells did not form crown-like structures or transform into foam cells. Our results suggest that cholesterol crystallization within hepatocyte lipid droplets and aggregation and activation of Kupffer cells in crown-like structures around such droplets represent an important, novel mechanism for progression of simple steatosis to NASH.
Figures
Similar articles
-
Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH.J Lipid Res. 2017 Jun;58(6):1067-1079. doi: 10.1194/jlr.M072454. Epub 2017 Apr 12. J Lipid Res. 2017. PMID: 28404639 Free PMC article.
-
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.J Lipid Res. 2015 Feb;56(2):277-85. doi: 10.1194/jlr.M053785. Epub 2014 Dec 17. J Lipid Res. 2015. PMID: 25520429 Free PMC article.
-
[Cholesterol metabolism and non-alcoholic steatohepatitis].Zhonghua Gan Zang Bing Za Zhi. 2016 Aug 20;24(8):623-627. doi: 10.3760/cma.j.issn.1007-3418.2016.08.014. Zhonghua Gan Zang Bing Za Zhi. 2016. PMID: 27788713 Review. Chinese.
-
Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.Toxicol Appl Pharmacol. 2020 Apr 15;393:114941. doi: 10.1016/j.taap.2020.114941. Epub 2020 Feb 29. Toxicol Appl Pharmacol. 2020. PMID: 32126212
-
Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.Hepatol Commun. 2022 Jan;6(1):12-35. doi: 10.1002/hep4.1801. Epub 2021 Aug 24. Hepatol Commun. 2022. PMID: 34558856 Free PMC article. Review.
Cited by
-
Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis increasing the risk of cerebrovascular complications.Nat Cardiovasc Res. 2023 Jun 26;2(7):656-672. doi: 10.1038/s44161-023-00295-x. Nat Cardiovasc Res. 2023. PMID: 38362263 Free PMC article.
-
Discrimination of lipid composition and cellular localization in human liver tissues by stimulated Raman scattering microscopy.J Biomed Opt. 2024 Jan;29(1):016008. doi: 10.1117/1.JBO.29.1.016008. Epub 2024 Jan 24. J Biomed Opt. 2024. PMID: 38269081 Free PMC article.
-
Efferocytosis in liver disease.JHEP Rep. 2023 Nov 16;6(1):100960. doi: 10.1016/j.jhepr.2023.100960. eCollection 2024 Jan. JHEP Rep. 2023. PMID: 38234410 Free PMC article. Review.
-
Overexpression of ORMDL3 confers sexual dimorphism in diet-induced non-alcoholic steatohepatitis.Mol Metab. 2024 Jan;79:101851. doi: 10.1016/j.molmet.2023.101851. Epub 2023 Dec 9. Mol Metab. 2024. PMID: 38081412 Free PMC article.
-
Mechanisms of liver fibrosis in metabolic syndrome.eGastroenterology. 2023 Jun;1(1):e100015. doi: 10.1136/egastro-2023-100015. eGastroenterology. 2023. PMID: 37946713 Free PMC article.
References
-
- Browning J. D., Szczepaniak L. S., Dobbins R., Nuremberg P., Horton J. D., Cohen J. C., Grundy S. M., Hobbs H. H. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 40: 1387–1395 - PubMed
-
- Bellentani S., Saccoccio G., Masutti F., Croce L. S., Brandi G., Sasso F., Cristanini G., Tiribelli C. 2000. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132: 112–117 - PubMed
-
- Williams C. D., Stengel J., Asike M. I., Torres D. M., Shaw J., Contreras M., Landt C. L., Harrison S. A. 2011. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 140: 124–131 - PubMed
-
- Matteoni C. A., Younossi Z. M., Gramlich T., Boparai N., Liu Y. C., McCullough A. J. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116: 1413–1419 - PubMed
-
- Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., Musso A., De Paolis P., Capussotti L., Salizzoni M., et al. 2002. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 123: 134–140 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
